Revolutionizing the treatment of chronic disease.

Leveraging our NanoPortal technology, we are developing a portfolio of highly differentiated products comprised of miniature, sub-dermal drug implants.

Our Pipeline

Indication
Feasibility
Pre-Clinical
Clinical
Market Size
Type 2 Diabetes
NPM-119

exenatide

>$20B
Human Obesity
NPM-115

high-dose exenatide

>$50B
Human Obesity
NPM-139

undisclosed molecule

>$50B
Feline Pre-Diabetes & Diabetes
OKV-119

exenatide

>$500M
Indication
Type 2 Diabetes
Feasibility
Pre-Clinical
Clinical
Market Size
NPM-119

exenatide

>$20B
Indication
Human Obesity
Feasibility
Pre-Clinical
Clinical
Market Size
NPM-115

high-dose exenatide

>$50B
Indication
Human Obesity
Feasibility
Pre-Clinical
Clinical
Market Size
NPM-139

undisclosed molecule

>$50B
Indication
Feline Pre-Diabetes & Diabetes
Feasibility
Pre-Clinical
Clinical
Market Size
OKV-119

exenatide

>$500M
Indication
Type 2 Diabetes
Feasibility
Pre-Clinical
Clinical
Market Size
NPM-119

exenatide

>$20B
Indication
Human Obesity
Feasibility
Pre-Clinical
Clinical
Market Size
NPM-115

high-dose exenatide

>$50B
Indication
Human Obesity
Feasibility
Pre-Clinical
Clinical
Market Size
NPM-139

undisclosed molecule

>$50B
Indication
Feline Pre-Diabetes & Diabetes
Feasibility
Pre-Clinical
Clinical
Market Size
OKV-119

exenatide

>$500M

NPM-119 Overview

A miniature, GLP-1 receptor agonist implant designed to address medication non-adherence and improve tolerability.

Built with our NanoPortal technology, NPM-119 is designed to provide steady, long-term therapeutic delivery of exenatide for at least six months.

By assuring medication adherence, NPM-119 may free patients with type 2 diabetes from burdens associated with oral and injectable medications, as well as provide confidence to physicians, caregivers and loved ones that patients are receiving the intended therapeutic benefits from their medicine.

Target

Under investigation for the treatment of type 2 diabetes.

Medication non-adherence affects an alarming number of patients – approximately 50%, including those taking daily pills. Non-adherence may contribute to the gap in real-world effectiveness compared to the efficacy reported from randomized, controlled, clinical trials.

Development

First-in-Human clinical trial.

In 2023, we submitted an Investigational New Drug application with the U.S. FDA to support the initiation of a First-in-Human clinical study of NPM-119 called LIBERATE-1. In parallel, we plan to pursue the option of conducting studies in Australia, including LIBERATE-1, as well.

LIBERATE-1 is the first clinical study investigating the effects of NPM-119 in patients with type 2 diabetes and of our platform NanoPortal implant technology.

NPM-115 Overview

A miniature, GLP-1 receptor agonist implant designed to address medication non-adherence and improve tolerability.

NPM-115, also leveraging our NanoPortal technology, is designed to provide steady, long-term therapeutic delivery of high-dose exenatide for at least six months.

By assuring medication adherence, NPM-115 may free patients with obesity from burdens associated with oral and injectable medications, as well as provide confidence to physicians, caregivers and loved ones that patients are receiving the intended therapeutic benefits from their medicine.

Target

Under investigation for the treatment of obesity.

Although the GLP-1 receptor agonist class has quickly outpaced previous anti-obesity medications due to superior efficacy and tolerability, medication non-adherence continues to affect an alarming number of patients – approximately 50%, including those taking daily pills. In fact, non-adherence may also contribute to the gap in real-world effectiveness compared to the efficacy reported from randomized, controlled, clinical trials.

Development

Preclinical Stage Investigations.

In response to the unprecedented growth and focus on the anti-obesity and weight loss markets, we formally established NPM-115 and initiated feasibility studies with high-dose exenatide in our proprietary NanoPortal implant technology. Ongoing development work with NPM-119 and additional studies with high-dose exenatide should help accelerate further development activities of NPM-115.